Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Longeveron Inc. (LGVN : NSDQ)

• Company Description    Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI. Number of Employees: 22

• Price / Volume Information    Yesterday's Closing Price: $8.19 Daily Weekly Monthly 20 Day Moving Average: 548,569 shares Shares Outstanding: 20.91 (millions) Market Capitalization: $171.27 (millions) Beta: -2.02 52 Week High: $45.00 52 Week Low: $2.84 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -33.74% -27.45% 12 Week 32.52% 48.94% Year To Date -32.15% -17.10%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1951 NW 7TH AVENUE SUITE 520 - MIAMI,FL 33136 USA ph: 305-909-0840 fax: - investorrelations@longeveron.com http://www.longeveron.com

• General Corporate Information    Officers Geoff Green - Chief Executive Officer Joshua M. Hare - Chairman and Director James Clavijo - Chief Financial Officer and Treasurer Paul Lehr - General Counsel and Secretary Donald M. Soffer - Director Peer Information Longeveron Inc. (CORR.) Longeveron Inc. (RSPI) Longeveron Inc. (CGXP) Longeveron Inc. (BGEN) Longeveron Inc. (GTBP) Longeveron Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 54303L104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/12/22 Share - Related Items Shares Outstanding: 20.91 Most Recent Split Date: (:1) Beta: -2.02 Market Capitalization: $171.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.99 Price/Cash Flow: - Price / Sales: 131.75 EPS Growth vs. Year Ago Period: 5.56% vs. Previous Quarter: 15.00% Sales Growth vs. Year Ago Period: -1.60% vs. Previous Quarter: 77.03% ROE 03/31/22 - -58.76 12/31/21 - -61.46 09/30/21 - -75.99 ROA 03/31/22 - -50.22 12/31/21 - -51.57 09/30/21 - -58.09 Current Ratio 03/31/22 - 13.28 12/31/21 - 13.06 09/30/21 - 10.18 Quick Ratio 03/31/22 - 13.28 12/31/21 - 13.06 09/30/21 - 10.18 Operating Margin 03/31/22 - -1,341.85 12/31/21 - -1,305.13 09/30/21 - -629.34 Net Margin 03/31/22 - -1,341.85 12/31/21 - -1,305.13 09/30/21 - -629.34 Pre-Tax Margin 03/31/22 - -1,341.85 12/31/21 - -1,305.13 09/30/21 - -629.34 Book Value 03/31/22 - 1.64 12/31/21 - 1.79 09/30/21 - 1.17 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.01 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.64

Powered by Zacks Investment Research ©